Patent Portfolio

The following table summarizes the key U.S. Patent estate of Biomoda.  Patent protection in numerous foreign countries, based on these domestic patents, is in place or pending.

U.S. Patent            Title  

 6,838,248              Compositions and Methods for Detecting Pre-Cancerous Conditions in

                              Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl)

                              Porphine

 7,384,764              Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-

                              Tetrakis (Carboxyphenyl) Porphine

 7,670,799              Compositions and Methods of Making 5, 10, 15, 20-Tetrakis

                              (Carboxyphenyl) Porphine (Pending)

 61/226,646             System and Method for Analyzing Samples Labeled with  

                              5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphine (TCPP) (Pending)

The following chart shows the current patents and their relationship to each other.

Trademarks

Biomoda has developed proprietary expertise specific to preparation of the assay kit and its application.  Biomoda has been granted the Trademarks CyPath^® and CyDx^® for chemical agents and preparations for medical and clinical laboratory diagnostic use and assay kits containing chemical preparations for medical and clinical laboratory diagnostic use. Marketing of the Cypath^® assay will be accomplished by training individual laboratories in the proper procedures for conducting the patented early lung cancer detection test. Biomoda intends to license with clinical laboratories as partners.   This is a strategic decision to protect our intellectual property by disclosing trade secret aspects only to licensed partners.  This strategy, in conjunction with the patents, will allow Biomoda to better protect its market position.  

 

Patent Counsel

Janeen Vilven-Doggett Ph.D., J.D. s a member of the New Mexico bar and a registered patent attorney. Dr. Vilven-Doggett received her B.A. in Biology from Baylor University in 1986 and her Ph.D. in Biomedical Sciences from the University of New Mexico in 1997. She received her J.D. (cum laude) from the University of New Mexico School of Law in 2001.  She is a shareholder with the law firm of Peacock Myers PC.